Waterfront Wealth Inc. Acquires Shares of 1,515 Agilent Technologies, Inc. (NYSE:A)

Waterfront Wealth Inc. acquired a new stake in shares of Agilent Technologies, Inc. (NYSE:A) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,515 shares of the medical research company’s stock, valued at approximately $211,000.

A number of other hedge funds have also recently bought and sold shares of A. Synovus Financial Corp grew its position in shares of Agilent Technologies by 2.3% in the 1st quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock worth $895,000 after acquiring an additional 153 shares in the last quarter. Blair William & Co. IL grew its position in shares of Agilent Technologies by 7.3% in the 1st quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company’s stock worth $3,785,000 after acquiring an additional 1,957 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Agilent Technologies by 52.1% in the 1st quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company’s stock worth $309,000 after acquiring an additional 799 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Agilent Technologies by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock worth $3,246,209,000 after acquiring an additional 261,435 shares in the last quarter. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Agilent Technologies by 10.8% in the 1st quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company’s stock worth $381,000 after purchasing an additional 281 shares during the last quarter.

Insider Activity at Agilent Technologies

In other news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Rodney Gonsalves sold 4,828 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total transaction of $719,372.00. Following the sale, the vice president now directly owns 21,329 shares in the company, valued at approximately $3,178,021. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Fields sold 1,658 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares in the company, valued at $7,935,235.84. The disclosure for this sale can be found here. Insiders have sold 61,610 shares of company stock worth $9,220,333 over the last three months.

Agilent Technologies Stock Down 1.0 %

A traded down $1.35 during trading on Thursday, reaching $133.20. 485,899 shares of the stock traded hands, compared to its average volume of 1,567,787. The stock has a market cap of $39.03 billion, a price-to-earnings ratio of 32.04, a price-to-earnings-growth ratio of 4.14 and a beta of 1.11. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $151.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The stock’s 50-day simple moving average is $141.22 and its two-hundred day simple moving average is $129.48.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the previous year, the company posted $1.37 earnings per share. The company’s quarterly revenue was down 5.5% compared to the same quarter last year. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.51 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be paid a dividend of $0.236 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.94 annualized dividend and a yield of 0.71%. Agilent Technologies’s dividend payout ratio is 22.38%.

Analyst Upgrades and Downgrades

A has been the topic of several recent research reports. UBS Group raised their price target on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. Oppenheimer raised their price target on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. lifted their target price on Agilent Technologies from $140.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and lifted their target price for the company from $145.00 to $163.00 in a research note on Friday, April 5th. Finally, Barclays boosted their price objective on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.